Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ADP-induced platelet activation

R N Puri1, R W Colman

  • 1Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA 19140, USA.

Critical Reviews in Biochemistry and Molecular Biology
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation.

The Journal of biological chemistry·2000
Same author

High-molecular-weight kininogen preadsorbed to glass surface markedly reduces neutrophil adhesion.

Biomaterials·2000
Same author

Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis.

Blood·2000
Same author

Biologic activities of the contact factors in vivo--potentiation of hypotension, inflammation, and fibrinolysis, and inhibition of cell adhesion, angiogenesis and thrombosis.

Thrombosis and haemostasis·1999
Same author

Plasma and tissue kallikrein in arthritis and inflammatory bowel disease.

Immunopharmacology·1999
Same author

The effect of high molecular weight kininogen on neutrophil adhesion to polymer surfaces.

Immunopharmacology·1999
Same journal

Conformational mobility of cationic voltage-gated ion channels.

Critical reviews in biochemistry and molecular biology·2026
Same journal

DNA polymerase I: structure, activity, and function in bacterial DNA replication and repair.

Critical reviews in biochemistry and molecular biology·2026
Same journal

The impact of HIV-1 Nef on CD4<sup>+</sup> T cells.

Critical reviews in biochemistry and molecular biology·2026
Same journal

Recent insights into bacterial ESCRT-III-mediated membrane remodeling.

Critical reviews in biochemistry and molecular biology·2026
Same journal

CRISPR-Cas9 editing of agricultural crops and medicinal plants: toward a cornucopia of natural products.

Critical reviews in biochemistry and molecular biology·2025
Same journal

RNA modifications as a means of self-recognition and immune protection.

Critical reviews in biochemistry and molecular biology·2025
See all related articles

Adenosine diphosphate (ADP) is crucial for platelet aggregation in thrombosis. This review details efforts to understand ADP-receptor mechanisms and develop targeted anti-platelet drugs.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Molecular Biology

Background:

  • Platelet activation by adenosine diphosphate (ADP) is central to hemostasis and arterial thrombosis, implicated in cardiovascular events like myocardial infarction and stroke.
  • ADP mediates platelet aggregation, shape change, secretion, calcium mobilization, and adenylyl cyclase inhibition, but the specific ADP-receptor remains elusive.
  • Understanding ADP-induced platelet responses is critical for developing effective anti-platelet therapies.

Purpose of the Study:

  • To review advancements in identifying the ADP-receptor protein.
  • To elucidate the signal transduction mechanisms underlying ADP-induced platelet activation.
  • To explore strategies for designing novel drugs that selectively target the ADP-receptor or its downstream pathways.

Main Methods:

Related Experiment Videos

  • Review of recent contributions from multidisciplinary research (chemistry, biochemistry, cell biology, pharmacology, molecular biology, clinical investigation).
  • Analysis of efforts to purify and clone the ADP-receptor.
  • Evaluation of newly developed drugs that selectively inhibit ADP-induced platelet responses.

Main Results:

  • Significant progress has been made in understanding ADP-induced platelet responses, despite ongoing controversies and challenges in receptor identification.
  • New classes of drugs have been developed, including those that mimic ADP and selectively target the ADP-receptor, and others that inhibit ADP-induced activation ex vivo.
  • These advancements provide a foundation for innovative therapeutic strategies.

Conclusions:

  • Continued research is essential to fully characterize the ADP-receptor and its signaling pathways.
  • Selective inhibition of ADP-mediated platelet activation holds therapeutic promise for preventing thrombotic events.
  • Developing targeted anti-platelet drugs is a key strategy for managing cardiovascular diseases.